Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Abstract In patients with existing ovarian function, there are some special aspects to adjuvant endocrine therapy in premenopausal hormone receptor-positive, HER2-negative (HR pos./HER2 neg.) breast cancer. Treatment options include tamoxifen or without a GnRH analog, and aromatase inhibitors analog. Furthermore, function is affected by previous chemotherapy. Both (+GnRH analogs) analogs combination supposed be indicated for at increased risk of recurrence. However, national international guidelines recommendations do not provide clear definition intermediate high risk; as result, decisions often made each patient on an individual basis. This also reflected the considerable variability levels, e.g., regard use + analogs. review summarizes data completed studies (e.g., SOFT, TEXT, EBCTCG meta-analyses) current multigene testing (TailorX, RxPonder, ADAPT), discusses rationale CLEAR-B), looks ahead future questions.